Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Usp9x Promotes Survival in Human Pancreatic Cancer and Its Inhibition Suppresses Pancreatic Ductal Adenocarcinoma In Vivo Tumor Growth.

Pal A, Dziubinski M, Di Magliano MP, Simeone DM, Owens S, Thomas D, Peterson L, Potu H, Talpaz M, Donato NJ.

Neoplasia. 2018 Feb;20(2):152-164. doi: 10.1016/j.neo.2017.11.007. Epub 2017 Dec 14.

2.

Usp9x regulates Ets-1 ubiquitination and stability to control NRAS expression and tumorigenicity in melanoma.

Potu H, Peterson LF, Kandarpa M, Pal A, Sun H, Durham A, Harms PW, Hollenhorst PC, Eskiocak U, Talpaz M, Donato NJ.

Nat Commun. 2017 Feb 15;8:14449. doi: 10.1038/ncomms14449.

3.

Induction of p53 suppresses chronic myeloid leukemia.

Peterson LF, Lo MC, Liu Y, Giannola D, Mitrikeska E, Donato NJ, Johnson CN, Wang S, Mercer J, Talpaz M.

Leuk Lymphoma. 2017 Sep;58(9):1-14. doi: 10.1080/10428194.2016.1272682. Epub 2017 Jan 13.

PMID:
28084835
4.

Anti-infective Activity of 2-Cyano-3-Acrylamide Inhibitors with Improved Drug-Like Properties against Two Intracellular Pathogens.

Passalacqua KD, Charbonneau ME, Donato NJ, Showalter HD, Sun D, Wen B, He M, Sun H, O'Riordan MX, Wobus CE.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):4183-96. doi: 10.1128/AAC.03021-15. Print 2016 Jul.

5.

Pre-clinical evidence of PIM kinase inhibitor activity in BCR-ABL1 unmutated and mutated Philadelphia chromosome-positive (Ph+) leukemias.

Curi DA, Beauchamp EM, Blyth GT, Arslan AD, Donato NJ, Giles FJ, Altman JK, Platanias LC.

Oncotarget. 2015 Oct 20;6(32):33206-16. doi: 10.18632/oncotarget.5091.

6.

Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies.

Peterson LF, Sun H, Liu Y, Potu H, Kandarpa M, Ermann M, Courtney SM, Young M, Showalter HD, Sun D, Jakubowiak A, Malek SN, Talpaz M, Donato NJ.

Blood. 2015 Jun 4;125(23):3588-97. doi: 10.1182/blood-2014-10-605584. Epub 2015 Mar 26.

7.
8.

Emerging potential of therapeutic targeting of ubiquitin-specific proteases in the treatment of cancer.

Pal A, Young MA, Donato NJ.

Cancer Res. 2014 Sep 15;74(18):4955-66. doi: 10.1158/0008-5472.CAN-14-1211. Epub 2014 Aug 29. Review.

9.

Small molecule deubiquitinase inhibitors promote macrophage anti-infective capacity.

Charbonneau ME, Gonzalez-Hernandez MJ, Showalter HD, Donato NJ, Wobus CE, O'Riordan MX.

PLoS One. 2014 Aug 5;9(8):e104096. doi: 10.1371/journal.pone.0104096. eCollection 2014.

10.

Usp5 links suppression of p53 and FAS levels in melanoma to the BRAF pathway.

Potu H, Peterson LF, Pal A, Verhaegen M, Cao J, Talpaz M, Donato NJ.

Oncotarget. 2014 Jul 30;5(14):5559-69.

11.

Chemical derivatives of a small molecule deubiquitinase inhibitor have antiviral activity against several RNA viruses.

Gonzalez-Hernandez MJ, Pal A, Gyan KE, Charbonneau ME, Showalter HD, Donato NJ, O'Riordan M, Wobus CE.

PLoS One. 2014 Apr 10;9(4):e94491. doi: 10.1371/journal.pone.0094491. eCollection 2014.

12.

Degrasyn-like symmetrical compounds: possible therapeutic agents for multiple myeloma (MM-I).

Peng Z, Maxwell DS, Sun D, Bhanu Prasad BA, Schuber PT Jr, Pal A, Ying Y, Han D, Gao L, Wang S, Levitzki A, Kapuria V, Talpaz M, Young M, Showalter HD, Donato NJ, Bornmann WG.

Bioorg Med Chem. 2014 Feb 15;22(4):1450-8. doi: 10.1016/j.bmc.2013.12.048. Epub 2014 Jan 3.

13.

Antiviral activity of a small molecule deubiquitinase inhibitor occurs via induction of the unfolded protein response.

Perry JW, Ahmed M, Chang KO, Donato NJ, Showalter HD, Wobus CE.

PLoS Pathog. 2012;8(7):e1002783. doi: 10.1371/journal.ppat.1002783. Epub 2012 Jul 5.

14.

Tyrphostin-like compounds with ubiquitin modulatory activity as possible therapeutic agents for multiple myeloma.

Peng Z, Pal A, Han D, Wang S, Maxwell D, Levitzki A, Talpaz M, Donato NJ, Bornmann W.

Bioorg Med Chem. 2011 Dec 1;19(23):7194-204. doi: 10.1016/j.bmc.2011.09.057. Epub 2011 Oct 7.

PMID:
22036213
15.

Antileukemic effects of AMPK activators on BCR-ABL-expressing cells.

Vakana E, Altman JK, Glaser H, Donato NJ, Platanias LC.

Blood. 2011 Dec 8;118(24):6399-402. doi: 10.1182/blood-2011-01-332783. Epub 2011 Oct 21.

16.

Imatinib is receptive to a collaboration.

Donato NJ.

Blood. 2011 Oct 13;118(15):4009-10. doi: 10.1182/blood-2011-08-373290. No abstract available.

17.

A small molecule deubiquitinase inhibitor increases localization of inducible nitric oxide synthase to the macrophage phagosome and enhances bacterial killing.

Burkholder KM, Perry JW, Wobus CE, Donato NJ, Showalter HD, Kapuria V, O'Riordan MX.

Infect Immun. 2011 Dec;79(12):4850-7. doi: 10.1128/IAI.05456-11. Epub 2011 Sep 12.

18.

Bcr-Abl adds another twist to cell fate.

Donato NJ.

Blood. 2011 Sep 8;118(10):2646-7. doi: 10.1182/blood-2011-07-366153. No abstract available.

19.

A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination.

Kapuria V, Levitzki A, Bornmann WG, Maxwell D, Priebe W, Sorenson RJ, Showalter HD, Talpaz M, Donato NJ.

Cell Signal. 2011 Dec;23(12):2076-85. doi: 10.1016/j.cellsig.2011.08.002. Epub 2011 Aug 9.

PMID:
21855629
20.

Protein cross-linking as a novel mechanism of action of a ubiquitin-activating enzyme inhibitor with anti-tumor activity.

Kapuria V, Peterson LF, Showalter HD, Kirchhoff PD, Talpaz M, Donato NJ.

Biochem Pharmacol. 2011 Aug 15;82(4):341-9. doi: 10.1016/j.bcp.2011.05.012. Epub 2011 May 19.

PMID:
21621524
21.

p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells.

Peterson LF, Mitrikeska E, Giannola D, Lui Y, Sun H, Bixby D, Malek SN, Donato NJ, Wang S, Talpaz M.

Leukemia. 2011 May;25(5):761-9. doi: 10.1038/leu.2011.7. Epub 2011 Feb 25.

PMID:
21350558
22.

Chronic myeloid leukemia stem cells and developing therapies.

Donato NJ, Peterson LF.

Leuk Lymphoma. 2011 Feb;52 Suppl 1:60-80. doi: 10.3109/10428194.2010.546921. Review.

PMID:
21299460
23.

Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis.

Sun H, Kapuria V, Peterson LF, Fang D, Bornmann WG, Bartholomeusz G, Talpaz M, Donato NJ.

Blood. 2011 Mar 17;117(11):3151-62. doi: 10.1182/blood-2010-03-276477. Epub 2011 Jan 19.

24.

Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis.

Kapuria V, Peterson LF, Fang D, Bornmann WG, Talpaz M, Donato NJ.

Cancer Res. 2010 Nov 15;70(22):9265-76. doi: 10.1158/0008-5472.CAN-10-1530. Epub 2010 Nov 2.

25.

Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells.

Carayol N, Vakana E, Sassano A, Kaur S, Goussetis DJ, Glaser H, Druker BJ, Donato NJ, Altman JK, Barr S, Platanias LC.

Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12469-74. doi: 10.1073/pnas.1005114107. Epub 2010 Jun 28.

26.

ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells.

Wu J, Meng F, Ying Y, Peng Z, Daniels L, Bornmann WG, Quintás-Cardama A, Roulston D, Talpaz M, Peterson LF, Donato NJ.

Leukemia. 2010 Apr;24(4):869-72. doi: 10.1038/leu.2009.300. Epub 2010 Jan 28. No abstract available.

27.

Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia.

Donato NJ, Fang D, Sun H, Giannola D, Peterson LF, Talpaz M.

Biochem Pharmacol. 2010 Mar 1;79(5):688-97. doi: 10.1016/j.bcp.2009.10.009. Epub 2009 Oct 27.

PMID:
19874801
28.

An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259.

Pene-Dumitrescu T, Peterson LF, Donato NJ, Smithgall TE.

Oncogene. 2008 Nov 27;27(56):7055-69. doi: 10.1038/onc.2008.330. Epub 2008 Sep 15.

29.

Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.

Wu J, Meng F, Kong LY, Peng Z, Ying Y, Bornmann WG, Darnay BG, Lamothe B, Sun H, Talpaz M, Donato NJ.

J Natl Cancer Inst. 2008 Jul 2;100(13):926-39. doi: 10.1093/jnci/djn188. Epub 2008 Jun 24.

30.

Transcriptional repression of c-Myb and GATA-2 is involved in the biologic effects of C/EBPalpha in p210BCR/ABL-expressing cells.

Soliera AR, Lidonnici MR, Ferrari-Amorotti G, Prisco M, Zhang Y, Martinez RV, Donato NJ, Calabretta B.

Blood. 2008 Sep 1;112(5):1942-50. doi: 10.1182/blood-2007-09-114975. Epub 2008 Jun 12.

31.

Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.

Wu J, Meng F, Lu H, Kong L, Bornmann W, Peng Z, Talpaz M, Donato NJ.

Blood. 2008 Apr 1;111(7):3821-9. doi: 10.1182/blood-2007-08-109330. Epub 2008 Jan 30.

32.
33.

Phase I clinical and pharmacodynamic evaluation of oral CI-1033 in patients with refractory cancer.

Zinner RG, Nemunaitis J, Eiseman I, Shin HJ, Olson SC, Christensen J, Huang X, Lenehan PF, Donato NJ, Shin DM.

Clin Cancer Res. 2007 May 15;13(10):3006-14.

34.

Degrasyn activates proteasomal-dependent degradation of c-Myc.

Bartholomeusz G, Talpaz M, Bornmann W, Kong LY, Donato NJ.

Cancer Res. 2007 Apr 15;67(8):3912-8.

35.

Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells.

Bartholomeusz GA, Talpaz M, Kapuria V, Kong LY, Wang S, Estrov Z, Priebe W, Wu J, Donato NJ.

Blood. 2007 Apr 15;109(8):3470-8. Epub 2007 Jan 3.

36.

Leukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBPalpha.

Ferrari-Amorotti G, Keeshan K, Zattoni M, Guerzoni C, Iotti G, Cattelani S, Donato NJ, Calabretta B.

Blood. 2006 Aug 15;108(4):1353-62. Epub 2006 May 2.

37.

Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model.

Trevino JG, Summy JM, Lesslie DP, Parikh NU, Hong DS, Lee FY, Donato NJ, Abbruzzese JL, Baker CH, Gallick GE.

Am J Pathol. 2006 Mar;168(3):962-72.

38.

Hyperthermia engages the intrinsic apoptotic pathway by enhancing upstream caspase activation to overcome apoptotic resistance in MCF-7 breast adenocarcinoma cells.

Klostergaard J, Leroux ME, Auzenne E, Khodadadian M, Spohn W, Wu JY, Donato NJ.

J Cell Biochem. 2006 May 15;98(2):356-69.

PMID:
16440323
40.

Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia.

Gao H, Lee BN, Talpaz M, Donato NJ, Cortes JE, Kantarjian HM, Reuben JM.

Leukemia. 2005 Nov;19(11):1905-11.

PMID:
16151467
41.
43.
44.

Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia.

Donato NJ, Wu JY, Stapley J, Lin H, Arlinghaus R, Aggarwal BB, Shishodia S, Albitar M, Hayes K, Kantarjian H, Talpaz M.

Cancer Res. 2004 Jan 15;64(2):672-7. Erratum in: Cancer Res. 2004 Mar 15;64(6):2306. Shishodin, Shishir [corrected to Shishodia, Shishir].

45.

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, Talpaz M.

Blood. 2003 Jan 15;101(2):690-8.

46.

Superior therapeutic profile of poly-L-glutamic acid-paclitaxel copolymer compared with taxol in xenogeneic compartmental models of human ovarian carcinoma.

Auzenne E, Donato NJ, Li C, Leroux E, Price RE, Farquhar D, Klostergaard J.

Clin Cancer Res. 2002 Feb;8(2):573-81.

48.

Differential effects of phosphatidylinositol-3/Akt-kinase inhibition on apoptotic sensitization to cytokines in LNCaP and PCc-3 prostate cancer cells.

Beresford SA, Davies MA, Gallick GE, Donato NJ.

J Interferon Cytokine Res. 2001 May;21(5):313-22.

PMID:
11429162
49.

Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer.

Shin DM, Donato NJ, Perez-Soler R, Shin HJ, Wu JY, Zhang P, Lawhorn K, Khuri FR, Glisson BS, Myers J, Clayman G, Pfister D, Falcey J, Waksal H, Mendelsohn J, Hong WK.

Clin Cancer Res. 2001 May;7(5):1204-13.

Supplemental Content

Loading ...
Support Center